A novel EZH2/NXPH4/CDKN2A axis is involved in regulating the proliferation and migration of non-small cell lung cancer cells

被引:17
|
作者
Yang, Zeng [1 ]
Wei, Bo [1 ]
Qiao, Anbang [1 ]
Yang, Popo [1 ]
Chen, Wenhui [1 ]
Zhen, Dezhi [1 ]
Qiu, Xiaojian [2 ]
机构
[1] Capital Med Univ, Beijing Tian Tan Hosp, Dept Thorac Surg, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Tian Tan Hosp, Dept Resp Med, Beijing, Peoples R China
关键词
NSCLC; NXPH4; CDKN2A; EZH2; cyclinD; TARGETING EZH2; SYNAPTIC FUNCTION; THERAPY; METHYLATION; P16(INK4A); EXPRESSION; NEUREXINS; PROGNOSIS; EVOLUTION; PROTEINS;
D O I
10.1093/bbb/zbab217
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
NXPH4 is discovered to be a neuropeptide-like glycoprotein, belonging to the Neurexophilins (Nxphs) family. NXPH4 shares a similar domain structure with NXPH1, which, however, is poorly understood in terms of its function. Bioinformatics analysis and experimental verification in this study confirmed the abnormal high expression of NXPH4 in non-small cell lung cancer (NSCLC) tissues and cells. Knockdown of NXPH4 by siRNA can inhibit the proliferation and migration of cells, resulting in significant cell cycle arrest in S1 phase. Furthermore, in NSCLC cells, NXPH4 was regulated by transcriptional activation of enhancer of zeste homolog 2 (EZH2) in its upstream. While downstream, NXPH4 could interact with CDKN2A and downregulate its protein stability, thus participating in the cell cycle regulation through interacting with cyclinD-CDK4/6-pRB-E2F signaling pathway. To sum up, the present study reveals a regulatory pathway of EZH2/NXPH4/CDKN2A in NSCLC, providing possible reference for understanding the function of NXPH4 in tumors.
引用
收藏
页码:340 / 350
页数:11
相关论文
共 50 条
  • [1] Prognosis of immunotherapy for non-small cell lung cancer with CDKN2A loss of function
    Zhao, Lu
    Zhou, Xiao
    Li, Hui
    Yin, Tiejun
    Jiang, Yueqiang
    JOURNAL OF THORACIC DISEASE, 2024, 16 (01) : 507 - 515
  • [2] FAK Executes Anti-Senescence via Regulating EZH2 Signaling in Non-Small Cell Lung Cancer Cells
    Chuang, Hsiang-Hao
    Huang, Ming-Shyan
    Zhen, Yen-Yi
    Chuang, Cheng-Hao
    Lee, Ying-Ray
    Hsiao, Michael
    Yang, Chih-Jen
    BIOMEDICINES, 2022, 10 (08)
  • [3] EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer
    Chunhua Xu
    Zhibo Hou
    Ping Zhan
    Wei Zhao
    Cunjie Chang
    Jue Zou
    Huidi Hu
    Yuanqin Zhang
    Xin Yao
    Like Yu
    Jun Yan
    Medical Oncology, 2013, 30
  • [4] EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer
    Xu, Chunhua
    Hou, Zhibo
    Zhan, Ping
    Zhao, Wei
    Chang, Cunjie
    Zou, Jue
    Hu, Huidi
    Zhang, Yuanqin
    Yao, Xin
    Yu, Like
    Yan, Jun
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [5] Tumor metabolism and prognostic role of EZH2 in non-small cell lung cancer
    Lopci, Egesta
    Rossi, Sabrina
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S982 - S988
  • [6] Detection of CDKN2A Gene Mutations in Patients with Non-Small Cell Lung Cancer Patients
    Wang, S.
    Xu, C.
    Wang, W.
    Zhuang, W.
    Song, Z.
    Zhu, Y.
    Chen, R.
    Guan, Y.
    Yi, X.
    Chen, Y.
    Chen, G.
    Fang, M.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1941 - S1941
  • [7] CDKN2a deficiency exposes a requirement for RhoA in maintenance of non-small cell lung cancer
    Konstantinidou, Georgia
    Torti, Francesca
    Batten, Kimberly
    Minna, John D.
    Shay, Jerry W.
    Scaglioni, Pier Paolo
    CANCER RESEARCH, 2011, 71
  • [8] Clinicopathological significance and prognostic role of EZH2 expression in non-small cell lung cancer
    Kim, Nae Yu
    Pyo, Jung-Soo
    PATHOLOGY RESEARCH AND PRACTICE, 2017, 213 (07) : 778 - 782
  • [9] EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer
    Geng, Jian
    Li, Xiao
    Zhou, Zhanmei
    Wu, Chin-Lee
    Dai, Meng
    Bai, Xiaoyan
    CANCER LETTERS, 2015, 359 (02) : 275 - 287
  • [10] CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
    Gutiontov, Stanley, I
    Turchan, William Tyler
    Spurr, Liam F.
    Rouhani, Sherin J.
    Chervin, Carolina Soto
    Steinhardt, George
    Lager, Angela M.
    Wanjari, Pankhuri
    Malik, Renuka
    Connell, Philip P.
    Chmura, Steven J.
    Juloori, Aditya
    Hoffman, Philip C.
    Ferguson, Mark K.
    Donington, Jessica S.
    Patel, Jyoti D.
    Vokes, Everett E.
    Weichselbaum, Ralph R.
    Bestvina, Christine M.
    Segal, Jeremy P.
    Pitroda, Sean P.
    SCIENTIFIC REPORTS, 2021, 11 (01)